A novel treatment approach for atopic dermatitis
- PMID: 39068954
- DOI: 10.1016/S0140-6736(24)01488-0
A novel treatment approach for atopic dermatitis
Conflict of interest statement
I have received consulting fees, speaker's and lecture fees, and payment for expert testimony from Almirall, Sanofi, Janssen, LEO Pharma, AbbVie, Pfizer, Boehringer Ingelheim, GSK, Regeneron, Eli Lilly, Celgene, Novartis, UCB, Merck, RAPT Therapeutics, Galderma, and BMS, and research support from Pfizer (grant paid to my institution), all outside the submitted work.
Comment on
-
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.Lancet. 2024 Aug 3;404(10451):445-460. doi: 10.1016/S0140-6736(24)01203-0. Epub 2024 Jul 24. Lancet. 2024. PMID: 39067461 Clinical Trial.
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical